Skip to content
Peptide research

Adamax

Also known as Semax Analog · Adamax Peptide · N-Acetyl Semax Adamantane · NASA
Category
Brain & Cognition
Administration routes
Nasal
Regulatory status
Not FDA-approved

What it is

Adamax is a synthetic Semax analog with an added adamantane group for stability, marketed for cognitive enhancement and neuroprotection. The human case is weak: BDNF upregulation and neuroprotection are only low-confidence, and cognitive gains remain speculative. No human safety data exist for Adamax itself, and safety from Semax may not hold for this modified molecule. Not an approved drug in the US; supply is unregulated research-grade product.

Read Full record

Studied uses & evidence

Studied uses(6)

  • BDNF Upregulation

    Low

    Semax rodent studies show BDNF and TrkB increases; no Adamax-specific data exists yet.

  • Enhanced Blood-Brain Barrier Penetration

    Speculative

    Mechanism-based only; adamantane conjugation aids CNS delivery but no Adamax uptake data exists.

  • Extended Duration of Action

    Speculative

    Mechanism-based only; acetylation may resist degradation, but no Adamax stability data exists.

Evidence limits

Evidence Level
Preclinical

Adamax has ZERO published peer-reviewed studies as of March 2026. All evidence is extrapolated from extensive Semax research (50+ preclinical studies, several human clinical trials in Russia for stroke therapy) and from general adamantane-modification pharmacology. The parent compound Semax has strong preclinical evidence for BDNF upregulation, neuroprotection, and cognitive effects in animal models, plus human clinical use in Russia/Ukraine for stroke recovery. However, Adamax's specific efficacy, optimal dosing, and safety profile in humans remain entirely unvalidated by published research.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(12)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No published human safety or toxicology data exists for Adamax specifically

    High
  • All safety extrapolations are from the parent compound Semax, which may not fully apply to the modified molecule

    High
  • Anecdotal reports of mild headaches and dizziness, typically dose-dependent

    Low
  • Nasal irritation with intranasal administration

    Low
  • Temporary mood or cognition changes during initial use

    Low
  • Insomnia reported when administered late in the day

    Low
  • Rare allergic reactions reported anecdotally

    Low
  • No long-term safety data available for chronic use

    High
  • Quality and purity vary among unregulated products sold online; not pharmaceutical-grade manufacturing

    High
  • Potential for unknown drug interactions due to lack of formal pharmacological profiling

    Moderate
  • Theoretical risk of excessive BDNF signaling with chronic high-dose use (no data to quantify)

    Theoretical
  • No established antidote or reversal protocol in case of adverse reaction

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.